0

Close
 
2022
Global Sepsis Diagnostic Market

Global Sepsis Diagnostic Market

by Product (Blood Culture Media, Instruments, Assay kits & Reagents, Software), by Technology (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry), by Method (Conventional Diagnostics, Automated Diagnostics), by Usability (Laboratory Testing, Point-of-care Testing), by Pathogen (Bacterial Sepsis, Fungal Sepsis, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030
Update Available On-Demand

LS : Diagnostics and Biotech
Report Code: A03908
Apr 2022 | Pages: 205
Tables: 180
Charts: 67

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

The South africa global sepsis diagnostic market is analyzed on the basis of method, product, technology, usability, pathogen.

Global Sepsis Diagnostic Market
By Method

Your browser does not support the canvas element.

Automated Diagnostics segment is projected to be the dominating segment throughout the forecast period.

Get more information on this report : Request Sample Pages

The report covers the drivers, restraints, and opportunities of the market. It focuses on the current market strategies adopted by the key players in the industry. These market players have been profiled in the report along with their strategic developments, such as partnership, expansion, collaboration, joint ventures, and others. The report also provides a detailed national market analysis on the basis of competitive scenario and how the competition will evolve in the coming years. The current market is also quantitatively analyzed to highlight the growth scenario of the market.

TOP IMPACTING FACTORS: MARKET SCENARIO ANALYSIS, TRENDS, DRIVERS, AND IMPACT ANALYSIS

The factors that are expected to drive/restrain the demand for South africa global sepsis diagnostic market are analyzed in the study. In addition, the cost impact on the market growth/decline has been thoroughly explained. Moreover, the potential factors are anticipated to provide lucrative opportunities for the market expansion. Furthermore, the detailed impact of the COVID-19 pandemic has been assessed on the growth/decline of the market.

COVID-19 IMPACT ANALYSIS

The outbreak of COVID-19 has radically affected most industry verticals across the globe. The report will cover the impact of COVID-19 on the South africa global sepsis diagnostic market, offering an explicit analysis of the scenario. It further provides the market strategies embraced by the major players during the pandemic. Moreover, the report encapsulates how COVID-19 has affected the supply chain. The market also states how the mass roll-out of vaccination is going to affect the South africa global sepsis diagnostic market in its post-COVID-19 impact analysis.

 

 Global Sepsis Diagnostic Market Report Highlights

Aspects Details
Market Size By 2030 USD 1.2 billion
Growth Rate CAGR of 7.8%
Forecast period 2020 - 2030
Report Pages 205
By Technology
  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry
By Method
  • Conventional Diagnostics
  • Automated Diagnostics
By Product
  • Blood Culture Media
  • Instruments
  • Assay kits & Reagents
  • Software
By Usability
  • Laboratory Testing
  • Point-of-care Testing
By Pathogen
  • Bacterial Sepsis
  • Fungal Sepsis
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players BioMerieux SA, Danaher Corporation, Thermo Fisher Scientific Inc., Nanosphere, Inc., T2 Biosystems, Inc, CEPHEID INC., Becton, Dickinson and Company, Bruker Corporation, Abbott Laboratories, Inc., F. HOFFMANN-LA ROCHE AG

Analyst Review

 

This section provides various opinions of the top-level CXOs in the sepsis diagnostics market industry. In accordance with several interviews conducted, the utilization of sepsis diagnostics techniques is expected to witness a significant rise with increase in disease diagnosis. The sepsis diagnostics market has piqued the interest of the healthcare industry, owing to its high accuracy and precise techniques

The CXOs further added that there have been remarkable advancements and some major developments in this market, such as devices with more throughput and accurate results. Owing to increase in chronic & infectious diseases, use of automated instruments, and rise in awareness regarding healthcare, North America is expected to emerge as a prominent leader in the global sepsis diagnostics market.

According to the perspectives of CXOs of leading companies in the market, rise in prevalence of infectious diseases, increase in cases of hospital-acquired infections, and technological advancements are some of the major factors that drive the growth of the global sepsis diagnostics market. However, high cost of automated diagnostic devices hampers the market growth.

As stated by CXOs, an increase in the incidence of chronic and infectious diseases boosts the demand for sepsis diagnostics techniques, as they are the simplest technique for diagnosis of diseases. Therefore, use of sepsis diagnostics techniques, such as molecular diagnostics, point-of-care testing, and immunodiagnostics, in standalone laboratories and hospitals is expected to fuel the market growth in the future.

In addition, the employment of sepsis diagnostics techniques is highest in North America, owing to increase in use of automated instruments, followed by Europe and Asia-Pacific. Furthermore, use of minimally invasive techniques is expected to boost the growth of the in vitro diagnostics market in Europe and Asia-Pacific.

 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. Low bargaining power of suppliers

      • 3.3.2. Low threat of new entrants

      • 3.3.3. Low threat of substitutes

      • 3.3.4. Low intensity of rivalry

      • 3.3.5. Low bargaining power of buyers

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. Rising incidence of hospital acquired infections
        • 3.4.1.2. The increase in pneumonia cases
        • 3.4.1.3. The increasing burden of sepsis

      • 3.4.2. Restraints

        • 3.4.2.1. High cost of automated diagnostic devices

      • 3.4.3. Opportunities

        • 3.4.3.1. Increase in government funding for sepsis-related research activities
        • 3.4.3.2. Development of rapid diagnosis /POC techniques for early sepsis diagnostics

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Blood Culture Media

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

    • 4.3. Instruments

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

    • 4.4. Assay kits & Reagents

      • 4.4.1. Key market trends, growth factors and opportunities

      • 4.4.2. Market size and forecast, by region

      • 4.4.3. Market share analysis by country

    • 4.5. Software

      • 4.5.1. Key market trends, growth factors and opportunities

      • 4.5.2. Market size and forecast, by region

      • 4.5.3. Market share analysis by country

  • CHAPTER 5: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Microbiology

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

    • 5.3. Molecular Diagnostics

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

    • 5.4. Immunoassays

      • 5.4.1. Key market trends, growth factors and opportunities

      • 5.4.2. Market size and forecast, by region

      • 5.4.3. Market share analysis by country

    • 5.5. Flow Cytometry

      • 5.5.1. Key market trends, growth factors and opportunities

      • 5.5.2. Market size and forecast, by region

      • 5.5.3. Market share analysis by country

  • CHAPTER 6: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Conventional Diagnostics

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Automated Diagnostics

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

  • CHAPTER 7: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY

    • 7.1. Overview

      • 7.1.1. Market size and forecast

    • 7.2. Laboratory Testing

      • 7.2.1. Key market trends, growth factors and opportunities

      • 7.2.2. Market size and forecast, by region

      • 7.2.3. Market share analysis by country

    • 7.3. Point-of-care Testing

      • 7.3.1. Key market trends, growth factors and opportunities

      • 7.3.2. Market size and forecast, by region

      • 7.3.3. Market share analysis by country

  • CHAPTER 8: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN

    • 8.1. Overview

      • 8.1.1. Market size and forecast

    • 8.2. Bacterial Sepsis

      • 8.2.1. Key market trends, growth factors and opportunities

      • 8.2.2. Market size and forecast, by region

      • 8.2.3. Market share analysis by country

    • 8.3. Fungal Sepsis

      • 8.3.1. Key market trends, growth factors and opportunities

      • 8.3.2. Market size and forecast, by region

      • 8.3.3. Market share analysis by country

    • 8.4. Others

      • 8.4.1. Key market trends, growth factors and opportunities

      • 8.4.2. Market size and forecast, by region

      • 8.4.3. Market share analysis by country

  • CHAPTER 9: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION

    • 9.1. Overview

      • 9.1.1. Market size and forecast By Region

    • 9.2. North America

      • 9.2.1. Key trends and opportunities

      • 9.2.2. Market size and forecast, by Product

      • 9.2.3. Market size and forecast, by Technology

      • 9.2.4. Market size and forecast, by Method

      • 9.2.5. Market size and forecast, by Usability

      • 9.2.6. Market size and forecast, by Pathogen

      • 9.2.7. Market size and forecast, by country

        • 9.2.7.1. U.S.
          • 9.2.7.1.1. Key market trends, growth factors and opportunities
          • 9.2.7.1.2. Market size and forecast, by Product
          • 9.2.7.1.3. Market size and forecast, by Technology
          • 9.2.7.1.4. Market size and forecast, by Method
          • 9.2.7.1.5. Market size and forecast, by Usability
          • 9.2.7.1.6. Market size and forecast, by Pathogen
        • 9.2.7.2. Canada
          • 9.2.7.2.1. Key market trends, growth factors and opportunities
          • 9.2.7.2.2. Market size and forecast, by Product
          • 9.2.7.2.3. Market size and forecast, by Technology
          • 9.2.7.2.4. Market size and forecast, by Method
          • 9.2.7.2.5. Market size and forecast, by Usability
          • 9.2.7.2.6. Market size and forecast, by Pathogen
        • 9.2.7.3. Mexico
          • 9.2.7.3.1. Key market trends, growth factors and opportunities
          • 9.2.7.3.2. Market size and forecast, by Product
          • 9.2.7.3.3. Market size and forecast, by Technology
          • 9.2.7.3.4. Market size and forecast, by Method
          • 9.2.7.3.5. Market size and forecast, by Usability
          • 9.2.7.3.6. Market size and forecast, by Pathogen

    • 9.3. Europe

      • 9.3.1. Key trends and opportunities

      • 9.3.2. Market size and forecast, by Product

      • 9.3.3. Market size and forecast, by Technology

      • 9.3.4. Market size and forecast, by Method

      • 9.3.5. Market size and forecast, by Usability

      • 9.3.6. Market size and forecast, by Pathogen

      • 9.3.7. Market size and forecast, by country

        • 9.3.7.1. Germany
          • 9.3.7.1.1. Key market trends, growth factors and opportunities
          • 9.3.7.1.2. Market size and forecast, by Product
          • 9.3.7.1.3. Market size and forecast, by Technology
          • 9.3.7.1.4. Market size and forecast, by Method
          • 9.3.7.1.5. Market size and forecast, by Usability
          • 9.3.7.1.6. Market size and forecast, by Pathogen
        • 9.3.7.2. France
          • 9.3.7.2.1. Key market trends, growth factors and opportunities
          • 9.3.7.2.2. Market size and forecast, by Product
          • 9.3.7.2.3. Market size and forecast, by Technology
          • 9.3.7.2.4. Market size and forecast, by Method
          • 9.3.7.2.5. Market size and forecast, by Usability
          • 9.3.7.2.6. Market size and forecast, by Pathogen
        • 9.3.7.3. U.K.
          • 9.3.7.3.1. Key market trends, growth factors and opportunities
          • 9.3.7.3.2. Market size and forecast, by Product
          • 9.3.7.3.3. Market size and forecast, by Technology
          • 9.3.7.3.4. Market size and forecast, by Method
          • 9.3.7.3.5. Market size and forecast, by Usability
          • 9.3.7.3.6. Market size and forecast, by Pathogen
        • 9.3.7.4. Italy
          • 9.3.7.4.1. Key market trends, growth factors and opportunities
          • 9.3.7.4.2. Market size and forecast, by Product
          • 9.3.7.4.3. Market size and forecast, by Technology
          • 9.3.7.4.4. Market size and forecast, by Method
          • 9.3.7.4.5. Market size and forecast, by Usability
          • 9.3.7.4.6. Market size and forecast, by Pathogen
        • 9.3.7.5. Spain
          • 9.3.7.5.1. Key market trends, growth factors and opportunities
          • 9.3.7.5.2. Market size and forecast, by Product
          • 9.3.7.5.3. Market size and forecast, by Technology
          • 9.3.7.5.4. Market size and forecast, by Method
          • 9.3.7.5.5. Market size and forecast, by Usability
          • 9.3.7.5.6. Market size and forecast, by Pathogen
        • 9.3.7.6. Rest of Europe
          • 9.3.7.6.1. Key market trends, growth factors and opportunities
          • 9.3.7.6.2. Market size and forecast, by Product
          • 9.3.7.6.3. Market size and forecast, by Technology
          • 9.3.7.6.4. Market size and forecast, by Method
          • 9.3.7.6.5. Market size and forecast, by Usability
          • 9.3.7.6.6. Market size and forecast, by Pathogen

    • 9.4. Asia-Pacific

      • 9.4.1. Key trends and opportunities

      • 9.4.2. Market size and forecast, by Product

      • 9.4.3. Market size and forecast, by Technology

      • 9.4.4. Market size and forecast, by Method

      • 9.4.5. Market size and forecast, by Usability

      • 9.4.6. Market size and forecast, by Pathogen

      • 9.4.7. Market size and forecast, by country

        • 9.4.7.1. Japan
          • 9.4.7.1.1. Key market trends, growth factors and opportunities
          • 9.4.7.1.2. Market size and forecast, by Product
          • 9.4.7.1.3. Market size and forecast, by Technology
          • 9.4.7.1.4. Market size and forecast, by Method
          • 9.4.7.1.5. Market size and forecast, by Usability
          • 9.4.7.1.6. Market size and forecast, by Pathogen
        • 9.4.7.2. China
          • 9.4.7.2.1. Key market trends, growth factors and opportunities
          • 9.4.7.2.2. Market size and forecast, by Product
          • 9.4.7.2.3. Market size and forecast, by Technology
          • 9.4.7.2.4. Market size and forecast, by Method
          • 9.4.7.2.5. Market size and forecast, by Usability
          • 9.4.7.2.6. Market size and forecast, by Pathogen
        • 9.4.7.3. Australia
          • 9.4.7.3.1. Key market trends, growth factors and opportunities
          • 9.4.7.3.2. Market size and forecast, by Product
          • 9.4.7.3.3. Market size and forecast, by Technology
          • 9.4.7.3.4. Market size and forecast, by Method
          • 9.4.7.3.5. Market size and forecast, by Usability
          • 9.4.7.3.6. Market size and forecast, by Pathogen
        • 9.4.7.4. India
          • 9.4.7.4.1. Key market trends, growth factors and opportunities
          • 9.4.7.4.2. Market size and forecast, by Product
          • 9.4.7.4.3. Market size and forecast, by Technology
          • 9.4.7.4.4. Market size and forecast, by Method
          • 9.4.7.4.5. Market size and forecast, by Usability
          • 9.4.7.4.6. Market size and forecast, by Pathogen
        • 9.4.7.5. South Korea
          • 9.4.7.5.1. Key market trends, growth factors and opportunities
          • 9.4.7.5.2. Market size and forecast, by Product
          • 9.4.7.5.3. Market size and forecast, by Technology
          • 9.4.7.5.4. Market size and forecast, by Method
          • 9.4.7.5.5. Market size and forecast, by Usability
          • 9.4.7.5.6. Market size and forecast, by Pathogen
        • 9.4.7.6. Rest of Asia-Pacific
          • 9.4.7.6.1. Key market trends, growth factors and opportunities
          • 9.4.7.6.2. Market size and forecast, by Product
          • 9.4.7.6.3. Market size and forecast, by Technology
          • 9.4.7.6.4. Market size and forecast, by Method
          • 9.4.7.6.5. Market size and forecast, by Usability
          • 9.4.7.6.6. Market size and forecast, by Pathogen

    • 9.5. LAMEA

      • 9.5.1. Key trends and opportunities

      • 9.5.2. Market size and forecast, by Product

      • 9.5.3. Market size and forecast, by Technology

      • 9.5.4. Market size and forecast, by Method

      • 9.5.5. Market size and forecast, by Usability

      • 9.5.6. Market size and forecast, by Pathogen

      • 9.5.7. Market size and forecast, by country

        • 9.5.7.1. Brazil
          • 9.5.7.1.1. Key market trends, growth factors and opportunities
          • 9.5.7.1.2. Market size and forecast, by Product
          • 9.5.7.1.3. Market size and forecast, by Technology
          • 9.5.7.1.4. Market size and forecast, by Method
          • 9.5.7.1.5. Market size and forecast, by Usability
          • 9.5.7.1.6. Market size and forecast, by Pathogen
        • 9.5.7.2. Saudi Arabia
          • 9.5.7.2.1. Key market trends, growth factors and opportunities
          • 9.5.7.2.2. Market size and forecast, by Product
          • 9.5.7.2.3. Market size and forecast, by Technology
          • 9.5.7.2.4. Market size and forecast, by Method
          • 9.5.7.2.5. Market size and forecast, by Usability
          • 9.5.7.2.6. Market size and forecast, by Pathogen
        • 9.5.7.3. South Africa
          • 9.5.7.3.1. Key market trends, growth factors and opportunities
          • 9.5.7.3.2. Market size and forecast, by Product
          • 9.5.7.3.3. Market size and forecast, by Technology
          • 9.5.7.3.4. Market size and forecast, by Method
          • 9.5.7.3.5. Market size and forecast, by Usability
          • 9.5.7.3.6. Market size and forecast, by Pathogen
        • 9.5.7.4. Rest of LAMEA
          • 9.5.7.4.1. Key market trends, growth factors and opportunities
          • 9.5.7.4.2. Market size and forecast, by Product
          • 9.5.7.4.3. Market size and forecast, by Technology
          • 9.5.7.4.4. Market size and forecast, by Method
          • 9.5.7.4.5. Market size and forecast, by Usability
          • 9.5.7.4.6. Market size and forecast, by Pathogen

  • CHAPTER 10: COMPETITIVE LANDSCAPE

    • 10.1. Introduction

    • 10.2. Top winning strategies

    • 10.3. Product Mapping of Top 10 Player

    • 10.4. Competitive Dashboard

    • 10.5. Competitive Heatmap

    • 10.6. Top player positioning, 2020

  • CHAPTER 11: COMPANY PROFILES

    • 11.1. BioMerieux SA

      • 11.1.1. Company overview

      • 11.1.2. Key Executives

      • 11.1.3. Company snapshot

      • 11.1.4. Operating business segments

      • 11.1.5. Product portfolio

      • 11.1.6. Business performance

    • 11.2. Thermo Fisher Scientific Inc.

      • 11.2.1. Company overview

      • 11.2.2. Key Executives

      • 11.2.3. Company snapshot

      • 11.2.4. Operating business segments

      • 11.2.5. Product portfolio

      • 11.2.6. Business performance

    • 11.3. Abbott Laboratories, Inc.

      • 11.3.1. Company overview

      • 11.3.2. Key Executives

      • 11.3.3. Company snapshot

      • 11.3.4. Operating business segments

      • 11.3.5. Product portfolio

      • 11.3.6. Business performance

    • 11.4. Becton, Dickinson and Company

      • 11.4.1. Company overview

      • 11.4.2. Key Executives

      • 11.4.3. Company snapshot

      • 11.4.4. Operating business segments

      • 11.4.5. Product portfolio

      • 11.4.6. Business performance

    • 11.5. Bruker Corporation

      • 11.5.1. Company overview

      • 11.5.2. Key Executives

      • 11.5.3. Company snapshot

      • 11.5.4. Operating business segments

      • 11.5.5. Product portfolio

      • 11.5.6. Business performance

    • 11.6. CEPHEID INC.

      • 11.6.1. Company overview

      • 11.6.2. Key Executives

      • 11.6.3. Company snapshot

      • 11.6.4. Operating business segments

      • 11.6.5. Product portfolio

    • 11.7. T2 Biosystems, Inc

      • 11.7.1. Company overview

      • 11.7.2. Key Executives

      • 11.7.3. Company snapshot

      • 11.7.4. Operating business segments

      • 11.7.5. Product portfolio

    • 11.8. Nanosphere, Inc.

      • 11.8.1. Company overview

      • 11.8.2. Key Executives

      • 11.8.3. Company snapshot

      • 11.8.4. Operating business segments

      • 11.8.5. Product portfolio

    • 11.9. F. HOFFMANN-LA ROCHE AG

      • 11.9.1. Company overview

      • 11.9.2. Key Executives

      • 11.9.3. Company snapshot

      • 11.9.4. Operating business segments

      • 11.9.5. Product portfolio

      • 11.9.6. Business performance

    • 11.10. Danaher Corporation

      • 11.10.1. Company overview

      • 11.10.2. Key Executives

      • 11.10.3. Company snapshot

      • 11.10.4. Operating business segments

      • 11.10.5. Product portfolio

      • 11.10.6. Business performance

  • LIST OF TABLES

  • TABLE 01. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 02. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR BLOOD CULTURE MEDIA, BY REGION, 2020-2030 ($MILLION)
    TABLE 03. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR INSTRUMENTS, BY REGION, 2020-2030 ($MILLION)
    TABLE 04. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2020-2030 ($MILLION)
    TABLE 05. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR SOFTWARE, BY REGION, 2020-2030 ($MILLION)
    TABLE 06. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 07. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR MICROBIOLOGY, BY REGION, 2020-2030 ($MILLION)
    TABLE 08. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2020-2030 ($MILLION)
    TABLE 09. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR IMMUNOASSAYS, BY REGION, 2020-2030 ($MILLION)
    TABLE 10. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR FLOW CYTOMETRY, BY REGION, 2020-2030 ($MILLION)
    TABLE 11. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 12. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR CONVENTIONAL DIAGNOSTICS, BY REGION, 2020-2030 ($MILLION)
    TABLE 13. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR AUTOMATED DIAGNOSTICS, BY REGION, 2020-2030 ($MILLION)
    TABLE 14. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 15. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR LABORATORY TESTING, BY REGION, 2020-2030 ($MILLION)
    TABLE 16. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR POINT-OF-CARE TESTING, BY REGION, 2020-2030 ($MILLION)
    TABLE 17. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 18. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR BACTERIAL SEPSIS, BY REGION, 2020-2030 ($MILLION)
    TABLE 19. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR FUNGAL SEPSIS, BY REGION, 2020-2030 ($MILLION)
    TABLE 20. GLOBAL SEPSIS DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
    TABLE 21. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION, 2020-2030 ($MILLION)
    TABLE 22. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 23. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 24. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 25. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 26. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 27. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 28. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 29. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 30. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 31. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 32. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 33. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 34. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 35. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 36. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 37. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 38. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 39. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 40. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 41. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 42. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 43. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 44. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 45. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 46. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 47. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 48. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 49. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 50. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 51. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 52. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 53. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 54. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 55. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 56. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 57. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 58. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 59. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 60. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 61. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 62. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 63. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 64. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 65. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 66. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 67. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 68. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 69. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 70. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 71. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 72. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 73. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 74. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 75. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 76. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 77. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 78. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 79. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 80. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 81. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 82. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 83. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 84. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 85. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 86. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 87. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 88. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 89. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 90. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 91. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 92. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 93. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 94. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 95. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 96. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 97. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 98. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 99. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 100. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 101. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 102. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 103. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 104. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 105. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 106. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 107. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 108. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 109. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 110. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 111. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 112. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 113. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 114. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 115. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 116. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 117. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 118. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 119. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 120. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 121. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 122. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 123. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 124. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 125. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 126. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 127. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 128. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 129. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 130. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 131. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 132. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 133. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 134. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 135. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 136. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 137. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
    TABLE 138. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030 ($MILLION)
    TABLE 139. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030 ($MILLION)
    TABLE 140. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030 ($MILLION)
    TABLE 141. BIOMERIEUX SA: KEY EXECUTIVES
    TABLE 142. BIOMERIEUX SA: COMPANY SNAPSHOT
    TABLE 143. BIOMERIEUX SA: PRODUCT SEGMENTS
    TABLE 144. BIOMERIEUX SA: PRODUCT PORTFOLIO
    TABLE 145. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
    TABLE 146. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
    TABLE 147. THERMO FISHER SCIENTIFIC INC.: SERVICE SEGMENTS
    TABLE 148. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
    TABLE 149. ABBOTT LABORATORIES, INC.: KEY EXECUTIVES
    TABLE 150. ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
    TABLE 151. ABBOTT LABORATORIES, INC.: PRODUCT SEGMENTS
    TABLE 152. ABBOTT LABORATORIES, INC.: PRODUCT PORTFOLIO
    TABLE 153. BECTON, DICKINSON AND COMPANY: KEY EXECUTIVES
    TABLE 154. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
    TABLE 155. BECTON, DICKINSON AND COMPANY: PRODUCT SEGMENTS
    TABLE 156. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
    TABLE 157. BRUKER CORPORATION: KEY EXECUTIVES
    TABLE 158. BRUKER CORPORATION: COMPANY SNAPSHOT
    TABLE 159. BRUKER CORPORATION: PRODUCT SEGMENTS
    TABLE 160. BRUKER CORPORATION: PRODUCT PORTFOLIO
    TABLE 161. CEPHEID INC.: KEY EXECUTIVES
    TABLE 162. CEPHEID INC.: COMPANY SNAPSHOT
    TABLE 163. CEPHEID INC.: PRODUCT SEGMENTS
    TABLE 164. CEPHEID INC.: PRODUCT PORTFOLIO
    TABLE 165. T2 BIOSYSTEMS, INC: KEY EXECUTIVES
    TABLE 166. T2 BIOSYSTEMS, INC: COMPANY SNAPSHOT
    TABLE 167. T2 BIOSYSTEMS, INC: PRODUCT SEGMENTS
    TABLE 168. T2 BIOSYSTEMS, INC: PRODUCT PORTFOLIO
    TABLE 169. NANOSPHERE, INC.: KEY EXECUTIVES
    TABLE 170. NANOSPHERE, INC.: COMPANY SNAPSHOT
    TABLE 171. NANOSPHERE, INC.: PRODUCT SEGMENTS
    TABLE 172. NANOSPHERE, INC.: PRODUCT PORTFOLIO
    TABLE 173. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
    TABLE 174. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
    TABLE 175. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
    TABLE 176. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
    TABLE 177. DANAHER CORPORATION: KEY EXECUTIVES
    TABLE 178. DANAHER CORPORATION: COMPANY SNAPSHOT
    TABLE 179. DANAHER CORPORATION: SERVICE SEGMENTS
    TABLE 180. DANAHER CORPORATION: PRODUCT PORTFOLIO

  • LIST OF FIGURES

  • FIGURE 1.GLOBAL SEPSIS DIAGNOSTIC MARKET SEGMENTATION
    FIGURE 2.GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030
    FIGURE 3.GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.GLOBAL SEPSIS DIAGNOSTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 11.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY PRODUCT,2020(%)
    FIGURE 12.COMPARATIVE SHARE ANALYSIS OF BLOOD CULTURE MEDIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INSTRUMENTS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ASSAY KITS & REAGENTS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF SOFTWARE GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 16.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY TECHNOLOGY,2020(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MICROBIOLOGY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF MOLECULAR DIAGNOSTICS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF IMMUNOASSAYS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF FLOW CYTOMETRY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 21.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY METHOD,2020(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CONVENTIONAL DIAGNOSTICS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF AUTOMATED DIAGNOSTICS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 24.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY USABILITY,2020(%)
    FIGURE 25.COMPARATIVE SHARE ANALYSIS OF LABORATORY TESTING GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 26.COMPARATIVE SHARE ANALYSIS OF POINT-OF-CARE TESTING GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 27.GLOBAL SEPSIS DIAGNOSTIC MARKET,BY PATHOGEN,2020(%)
    FIGURE 28.COMPARATIVE SHARE ANALYSIS OF BACTERIAL SEPSIS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 29.COMPARATIVE SHARE ANALYSIS OF FUNGAL SEPSIS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHERS GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030(%)
    FIGURE 31.GLOBAL SEPSIS DIAGNOSTIC MARKET BY REGION,2020
    FIGURE 32.U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 33.CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 34.MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 35.GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 36.FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 37.U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 38.ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 39.SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 40.REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 41.JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 42.CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 43.AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 44.INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 45.SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 46.REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 47.BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 48.SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 49.SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 50.REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET,2020-2030($MILLION)
    FIGURE 51. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 55.COMPETITIVE DASHBOARD
    FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 57..: NET SALES ,($MILLION)
    FIGURE 58.BIOMERIEUX SA.: NET SALES ,($MILLION)
    FIGURE 59.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
    FIGURE 60.ABBOTT LABORATORIES, INC..: NET SALES ,($MILLION)
    FIGURE 61.BECTON, DICKINSON AND COMPANY.: NET SALES ,($MILLION)
    FIGURE 62.BRUKER CORPORATION.: NET SALES ,($MILLION)
    FIGURE 63.BECKMAN COULTER, INC..: NET SALES ,($MILLION)
    FIGURE 64.T2 BIOSYSTEMS, INC.: NET SALES ,($MILLION)
    FIGURE 65.NANOSPHERE, INC..: NET SALES ,($MILLION)
    FIGURE 66.HOFFMANN-LA ROCHE LTD.: NET SALES ,($MILLION)
    FIGURE 67.DANAHER CORPORATION.: NET SALES ,($MILLION)

 
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The upcoming trends of Global Sepsis Diagnostic Market in the world includes increase in government funding for sepsis-related research activities and rise in prevalence of infectious disease further drive the market growth

A. The leading application of Global Sepsis Diagnostic Market includes Microbiology, Molecular Diagnostics, Immunoassays, and Flow Cytometry

A. North America is the largest regional market for Global Sepsis Diagnostic.

A. Global Sepsis Diagnostic is projected to reach $1207.58 million by 2030, registering a CAGR of 7.8% from 2021 to 2030.

A. The top companies to hold the market share in Global Sepsis Diagnostic includes BioMerieux, Thermo Fisher Scientific Inc., Abbott Laboratories, Inc., Becton, Dickinson and Company, Bruker Corporation, Beckman Coulter, Inc., T2 Biosystems, Inc., Nanosphere, Inc., Hoffmann-LA Roche Ltd., Danaher Corporation.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Global Sepsis Diagnostic Market

Start reading instantly.
This Report and over 67,069+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)

  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers